KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Income from Continuing Operations (2020 - 2023)

AbCellera Biologics' Income from Continuing Operations history spans 4 years, with the latest figure at 47150000.0 for Q4 2023.

  • For the quarter ending Q4 2023, Income from Continuing Operations fell 57.73% year-over-year to 47150000.0, compared with a TTM value of 146398000.0 through Dec 2023, down 192.35%, and an annual FY2024 reading of 162857000.0, down 11.24% over the prior year.
  • Income from Continuing Operations for Q4 2023 was 47150000.0 at AbCellera Biologics, down from 28610000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 168573000.0 in Q1 2022, with the low at 47150000.0 in Q4 2023.
  • Average Income from Continuing Operations over 4 years is 20541500.0, with a median of 2508000.0 recorded in 2020.
  • Biggest YoY gain for Income from Continuing Operations was 5700.62% in 2021; the steepest drop was 693.91% in 2021.
  • Tracing ABCL's Income from Continuing Operations over 4 years: stood at 161160000.0 in 2020, then crashed by 62.8% to 59948000.0 in 2021, then plummeted by 149.86% to 29893000.0 in 2022, then plummeted by 57.73% to 47150000.0 in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Income from Continuing Operations are 47150000.0 (Q4 2023), 28610000.0 (Q3 2023), and 30528000.0 (Q2 2023).